Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Vertex

Stock Market Rises In Range; Palantir, AMD, Shopify Lead Huge Earnings Movers: Weekly Review

The stock market indexes had big weekly gains despite some daily swings. Palantir and Shopify were among huge earnings movers.

Investors Business Daily

Weakness In Vertex Stock Seen As Buying Opportunity

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) stock is falling on Tuesday after the company’s pain data overshadowed strong second-quarter earnings.

Benzinga

Stock Market Today: Dow Retreats After Back-And-Forth Action; Palantir Makes This Bold Move (Live Coverage)

The major indexes ended the session in negative territory Tuesday.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Vertex Pharmaceuticals Stock Dives After Q2 Earnings, Phase 2 Results For VX-993

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported financial results for the second quarter after the market close on Monday. Here’s a rundown of the report.

Benzinga

Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat

Vertex stock nose-dived Tuesday after the biotech company said it wouldn't advance its next-generation pain drug into additional testing.

Investors Business Daily

Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know

Vertex Pharmaceuticals is all set to release its fiscal second-quarter earnings next month, and analysts project a robust triple-digit earnings growth.

Barchart

How Is Vertex Pharmaceuticals’ Stock Performance Compared to Other Biotech Stocks?

Vertex Pharmaceuticals has outperformed its biotech peers over the past year, yet Wall Street analysts maintain a reasonably optimistic outlook on its future potential.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Best Biotech Stocks to Buy in 2025

Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.

MarketBeat

Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks

Vertex stock skidded Tuesday on a series of first-quarter setbacks that included light sales, slow uptake for two drugs and a paused study.

Investors Business Daily

The IT challenge of real-time e-invoicing amid compliance shifts

Kathya Capote Peimbert at Vertex explains the business imperative of real-time e-invoicing amid regulatory changes.

TechRadar

Painkillers without the addiction? The new wave of non-opioid pain relief

Pharma firms are developing drugs that avoid the brain’s opioid receptors to minimise the risks of dependence and overdoses, but not all experts are convinced

The Guardian - UK

It's your last chance to buy one of our all-time favorite Shark upright vacuums in the Walmart sale – I'm a vacuum tester, and it's a seriously worthy upgrade

The Shark Vertex DuoClean PowerFin Upright Vacuum is now heavily discounted and brilliant for busy homes

Homes & Gardens

Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector?

Vertex Pharmaceuticals has outperformed relative to the healthcare sector over the past year, yet Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart

“We’ve never been limited to traditional categories” – Arc'teryx goes all in on technical mountain running shoes for 2025

2025 brings some exciting new technical runners from the Canadian brand, including a running shoe you can climb in

Advnture

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?

Vertex Pharmaceuticals has lagged behind the broader market over the past year, and Wall Street analysts are cautiously optimistic about the stock’s future.

Investors Business Daily

Stocks With Rising Composite Ratings: Vertex

Vertex saw its IBD SmartSelect Composite Rating jump to 96 Tuesday, up from 92 the day before.

Investors Business Daily

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.

Despite "another impressive quarterly revenue beat" on Tuesday and solid guidance, Vertex stock dipped on light profit.

Salon

Is a new painkiller too good to be true?

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.

The Independent UK

FDA approves new type of non-opioid pain medication in two decades

The new drug will be many times more expensive than a standard opioid option

Investors Business Daily

Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller

Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.

The Independent UK

£1.65m gene-editing therapy offers hope of cure for some blood disorder patients

The treatment uses gene-editing tool Crispr, which earned its inventors the Nobel Prize in chemistry in 2020.

The Independent UK

FDA approves new painkiller that shows promise and challenges of opioid alternatives

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids

MarketBeat

Vertex's Pain Drug: Big Pharma's Next Major Success?

Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.

Barchart

Vertex Pharmaceuticals Earnings Preview: What to Expect

With Vertex Pharmaceuticals gearing up to release its fourth-quarter earnings next month, analysts predict a single-digit drop in profit.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.